Abstract

Review Article

Risk factor of liver metastases in breast cancer

Akram Yazdani*

Published: 11 December, 2019 | Volume 3 - Issue 1 | Pages: 063-065

Objective: The liver is the second most common site of distant metastases from breast cancer. We investigated the risk factor liver metastasis in patients with breast cancer.

Methods: We studied Age, Menopausal status, Histologic Type, Tumor size, Number of cancerous axillary lymph nodes, in two groups with liver metastases with logistic regression to identify independent liver metastasis risk factors in breast cancer patients.

Results: Age, menopausal status, number of cancerous axillary lymph nodes and tumor size are the independent risk factors liver metastases in patients with breast cancer.

Conclusion: The increase number of cancerous axillary lymph nodes and tumor size may be diagnostic markers for liver metastases from breast cancer.

Read Full Article HTML DOI: 10.29328/journal.acst.1001011 Cite this Article Read Full Article PDF

Keywords:

Liver metastases; Breast cancer; Prognostic facto

References

  1. Jemal A, Siegel R, Xu J. Cancer statistics CA. Cancer J Clin. 2010; 60: 277-300. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20610543
  2. Er O et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008; 14: 62-68. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18303485
  3. Cao R, Wang L. Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer. Cancer Biol Med. 2012; 9: 57-62. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23691457
  4. Wyld L, Gutteridge E, Pinder S. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003; 89: 284-290. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12865918
  5. Saad R, Luckasevic T, Noga C, Johnson D, Silverman J. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fineneedle aspiration cytology. Diagn Cytopathol. 2004; 30: 1-6. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14696137
  6. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17954709
  7. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991; 64: 154-158. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1854615
  8. Lee J, Park S, Park J, Cho J, Kim S, et al. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol. 2013; 25: 1225-1231. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23230137
  9. Prabasheela B, Baskaran S, Arivazhagan R. Evaluation of alkaline phosphatase in pre and post operative breast cancer patients Short report Evaluation of alkaline phosphatase in pre and post operative breast cancer patients. Int J Biol Med Res. 2012; 3: 1536-1537.
  10. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D,et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence : a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2007; 18: 701-708. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17237474
  11. Crivellari D, Price K, Hagen M. Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG). Ann Oncol. 1995; 6: 769-776. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8589013
  12. Selzner M, Morse MA, Vredenburgh JJ, Meyers WC. Liver metastases from breast cancer : Long-term survival after curative resection. Surgery. 2000; 127: 383-389. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10776428
  13. Liska V, Holubec L Jr, Treska V, Vrzalova J, Skalicky T, et al. Evaluation of Tumour Markers as Differential Diagnostic Tool in Patients with Suspicion of Liver Metastases from Breast Cancer. Anticancer Res. 2011; 31: 1447-1451. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21508401
  14. Al-Jarallah M, Behbehani A, El-Nass SA, Temim L, Ebraheem AK. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol. 1993; 19: 74-79. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8436243
  15. Yerushalmi R. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol. 2012; 23: 338-345. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21543625
  16. Huang P, Lan M, Peng A, Qing-fu Y, Wen-zhao C, et al. Serum calcium , alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer. PLoS One. 2017; 12: 1-8. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28902911
  17. Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone Metastasis Prognostic Factors in Breast Cancer. Breast Cancer Basic Clin. Res. 2019; 13: 117822341983097. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30828246
  18. Van Hoof VO, Van Oosterom AT, Lepoutre L, De Broe ME. Alkaline phosphatase isoenzyme patterns in malignant disease. Clin Chem. 1992; 32: 2546-2551. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1458597
  19. Stieber P, Nagel D, Ritzke C, Rossler N, Kirsch C, et al. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma. Eur J Clin Chem Clin Biochem. 1992; 30: 809-814. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1489855
  20. Ramaswamy G, Rao VR, Krishnamoorthy L, Ramesh G, Gomathy R, et al. Serum levels of bone alkaline phosphatase in breast and prostate cancer with bone metastasis. Indian Journalof ClinBiochem. 2000; 15: 110-113. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23105250
  21. Lamerz R, Stieber P, Fateh-Moghadam A. Serum marker combinations in human breast cancer (review). In Vivo (Brooklyn). 1993; 7: 607-613. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8193281
  22. Coombes R, Powles TJ, Gazet JC, Nash AG, Ford HT, et al. Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet. 1980; 1: 296-298. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6101748
  23. Chandrakanth K, Kpyati A, Murthy DJ. Significance of serum total alkaline phosphatase levels in breast cancer. Int J Clin Biomed Res. 2016; 2: 13-15.
  24. Faiz AS, Guo S, Kaveney A, Philipp CS. Venous thrombosis and breast cancer in older women: Racial differences in risk factors and mortality. Thromb Res. 2018; 171: 130-135. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30296717
  25. Han LJ, Seong-wook L. The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches. Gastroenterol ResPract. 2017; 2017: 11. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28588612

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More